

## References

### Dose frication of COVID-19 vaccines

1. Anderson, E. J. *et al.* Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. *N Engl J Med* **383**, 2427-2438, doi:10.1056/NEJMoa2028436 (2020).
2. Chappell, K. J. *et al.* Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. *Lancet Infect Dis*, doi:10.1016/s1473-3099(21)00200-0 (2021).
3. Che, Y. *et al.* Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults. *Clin Infect Dis*, doi:10.1093/cid/ciaa1703 (2020).
4. Chu, L. *et al.* A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. *Vaccine* **39**, 2791-2799, doi:10.1016/j.vaccine.2021.02.007 (2021).
5. Ella, R. *et al.* Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. *Lancet Infect Dis* **21**, 950-961, doi:10.1016/s1473-3099(21)00070-0 (2021).
6. Ella, R. *et al.* Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. *Lancet Infect Dis* **21**, 637-646, doi:10.1016/s1473-3099(20)30942-7 (2021).
7. Formica, N. *et al.* Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial. *PLoS Med* **18**, e1003769, doi:10.1371/journal.pmed.1003769 (2021).
8. Goepfert, P. A. *et al.* Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study. *Lancet Infect Dis* **21**, 1257-1270, doi:10.1016/s1473-3099(21)00147-x (2021).
9. Guo, W. *et al.* Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial. *EClinicalMedicine* **38**, 101010, doi:10.1016/j.eclinm.2021.101010 (2021).
10. Han, B. *et al.* Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. *Lancet Infect Dis*, doi:10.1016/s1473-3099(21)00319-4 (2021).
11. Hsieh, S. M. *et al.* Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study. *EClinicalMedicine* **38**, 100989, doi:10.1016/j.eclinm.2021.100989 (2021).
12. Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med* **383**, 1920-1931, doi:10.1056/NEJMoa2022483 (2020).
13. Keech, C. *et al.* Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. *N Engl J Med* **383**, 2320-2332, doi:10.1056/NEJMoa2026920 (2020).

14. Kremsner, P. G. *et al.* Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. *Wien Klin Wochenschr*, 1-11, doi:10.1007/s00508-021-01922-y (2021).
15. Li, J. *et al.* Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. *Nat Med* **27**, 1062-1070, doi:10.1038/s41591-021-01330-9 (2021).
16. Meng, F. Y. *et al.* Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials. *Signal Transduct Target Ther* **6**, 271, doi:10.1038/s41392-021-00692-3 (2021).
17. Momin, T. *et al.* Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. *EClinicalMedicine* **38**, 101020, doi:10.1016/j.eclinm.2021.101020 (2021).
18. Mulligan, M. J. *et al.* Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature* **586**, 589-593, doi:10.1038/s41586-020-2639-4 (2020).
19. Pan, H. X. *et al.* Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. *Chin Med J (Engl)* **134**, 1289-1298, doi:10.1097/cm9.0000000000001573 (2021).
20. Richmond, P. *et al.* Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. *Lancet* **397**, 682-694, doi:10.1016/s0140-6736(21)00241-5 (2021).
21. Sadoff, J. *et al.* Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine. *N Engl J Med* **384**, 1824-1835, doi:10.1056/NEJMoa2034201 (2021).
22. Sahin, U. *et al.* COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. *Nature* **586**, 594-599, doi:10.1038/s41586-020-2814-7 (2020).
23. Shu, Y. J. *et al.* Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial. *Chin Med J (Engl)* **134**, 1967-1976, doi:10.1097/cm9.0000000000001702 (2021).
24. Tebas, P. *et al.* Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial. *EClinicalMedicine* **31**, 100689, doi:10.1016/j.eclinm.2020.100689 (2021).
25. Walsh, E. E. *et al.* Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *N Engl J Med* **383**, 2439-2450, doi:10.1056/NEJMoa2027906 (2020).
26. Walter, E. B. *et al.* Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. *N Engl J Med*, doi:10.1056/NEJMoa2116298 (2021).
27. Ward, B. J. *et al.* Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. *Nat Med* **27**, 1071-1078, doi:10.1038/s41591-021-01370-1 (2021).
28. Wu, S. *et al.* Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. *Lancet Infect Dis*, doi:10.1016/s1473-3099(21)00396-0 (2021).

29. Wu, Z. *et al.* Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis* **21**, 803-812, doi:10.1016/s1473-3099(20)30987-7 (2021).
30. Xia, S. *et al.* Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. *Jama* **324**, 951-960, doi:10.1001/jama.2020.15543 (2020).
31. Xia, S. *et al.* Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. *Lancet Infect Dis* **21**, 39-51, doi:10.1016/s1473-3099(20)30831-8 (2021).
32. Xia, S. *et al.* Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. *Lancet Infect Dis*, doi:10.1016/s1473-3099(21)00462-x (2021).
33. Yang, S. *et al.* Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. *Lancet Infect Dis* **21**, 1107-1119, doi:10.1016/s1473-3099(21)00127-4 (2021).
34. Zhang, J. *et al.* Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial. *Emerg Microbes Infect* **10**, 1589-1597, doi:10.1080/22221751.2021.1951126 (2021).
35. Zhang, Y. *et al.* Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis* **21**, 181-192, doi:10.1016/s1473-3099(20)30843-4 (2021).
36. Zhu, F. *et al.* Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial. *Clin Infect Dis*, doi:10.1093/cid/ciab845 (2021).
37. Zhu, F. C. *et al.* Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet* **396**, 479-488, doi:10.1016/s0140-6736(20)31605-6 (2020).
38. Zhu, F. C. *et al.* Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. *Lancet* **395**, 1845-1854, doi:10.1016/s0140-6736(20)31208-3 (2020).

#### **Cross-reactions between SARS-Cov-2 variants**

1. Cromer, D. *et al.* Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *Lancet Microbe* **3**, e52-e61, doi:10.1016/S2666-5247(21)00267-6 (2022).
2. Carreno, J. M. *et al.* Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. *Nature*, doi:10.1038/s41586-022-04399-5 (2021).

### **Vaccine effectiveness against SARS-Cov-2 variants**

1. Abu-Raddad, L. J., Chemaitelly, H., Butt, A. A. & National Study Group for, C.-V. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *N Engl J Med* **385**, 187-189, doi:10.1056/NEJMc2104974 (2021).
2. Lopez Bernal, J. *et al.* Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med* **385**, 585-594, doi:10.1056/NEJMoa2108891 (2021).
3. Heath, P. T. *et al.* Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine. *N Engl J Med*, doi:10.1056/NEJMoa2107659 (2021).
4. Sheikh, A. *et al.* SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet* **397**, 2461-2462, doi:10.1016/S0140-6736(21)01358-1 (2021).
5. Nasreen, S. *et al.* Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario. *Nat Microbiol* **7**, 379-385, doi:10.1038/s41564-021-01053-0 (2022).
6. Chemaitelly, H. *et al.* mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. *Nat Med* **27**, 1614-1621, doi:10.1038/s41591-021-01446-y (2021).
7. Madhi, S. A. *et al.* Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. *N Engl J Med* **384**, 1885-1898, doi:10.1056/NEJMoa2102214 (2021).
8. Tang, P. *et al.* BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. *Nat Med* **27**, 2136-2143, doi:10.1038/s41591-021-01583-4 (2021).
9. Li, X. N. *et al.* Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. *Emerg Microbes Infect* **10**, 1751-1759, doi:10.1080/22221751.2021.1969291 (2021).
10. Tseng, H. F. *et al.* Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. *Nat Med*, doi:10.1038/s41591-022-01753-y (2022).
11. Collie, S., Champion, J., Moultrie, H., Bekker, L. G. & Gray, G. Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa. *N Engl J Med* **386**, 494-496, doi:10.1056/NEJMc2119270 (2022).
12. Keech, C. *et al.* Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. *N Engl J Med* **383**, 2320-2332, doi:10.1056/NEJMoa2026920 (2020).